Xi'an International Medical Investment 国际医学
21 significant filings since 29 May 2026: 1 on share pledge, 10 on share issue and 3 on pledge released, and 2 other kinds. The latest, on 8 Sep 2026: 关于向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的公告. On 14 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 59.99% to 61.81% from the same period a year earlier.
自 29 May 2026 起有 21 份重大公告：share pledge 1 份、share issue 10 份、pledge released 3 份，另有 2 类。最新一份（8 Sep 2026）：关于向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的公告。14 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 59.99% 至 61.81%。
Price History 价格走势
5 sessions 个交易日, 18 Sep to 24 Sep 2026 · Live one-minute prices · High 最高 ¥4.39 · Low 最低 ¥4.18 · +0.70% on the previous close of ¥4.27The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 24 Aug 2023 | 东吴证券 | 朱国广,冉胜男 | Outperform 增持 | ▲ | Buy 买入 |
| 28 Jan 2021 | 申港证券 | 曹旭特 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东海证券 | 杜永宏 | Buy 买入 | 17 Sep 2026 | 2 | — |
| 西南证券 | 杜向阳 | Unrated | 8 May 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。